cyclin C Inhibitors

The class of cyclin C inhibitors comprises a diverse range of chemical compounds that exert inhibitory effects on cyclin-dependent kinases (CDKs), specifically targeting cyclin C-associated complexes. These inhibitors disrupt the cell cycle and interfere with downstream cellular processes regulated by cyclin C, representing a multifaceted approach to modulating cyclin C function. One prominent group of inhibitors includes flavopiridol, purvalanol A, roscovitine, indirubin, kenpaullone, dinaciclib, SNS-032, PHA-793887, AZD5438, R547, NU6027, and AT7519. These inhibitors act by selectively targeting CDK2 and CDK3, among other CDKs, inhibiting their kinase activities and, consequently, disrupting the normal progression of the cell cycle. Their impact on CDK3/cyclin C complexes results in the inhibition of phosphorylation events regulated by cyclin C, leading to a blockade of downstream cellular processes dependent on cyclin C-associated kinase activity. Flavopiridol, for instance, is a potent CDK inhibitor that interferes with cyclin C-associated functions, disrupting cell cycle progression. Similarly, purvalanol A and roscovitine selectively inhibit CDK2 and CDK3, affecting cyclin C-associated complexes and impeding cellular processes regulated by cyclin C. Indirubin, kenpaullone, dinaciclib, SNS-032, PHA-793887, AZD5438, R547, NU6027, and AT7519 exhibit similar mechanisms of action, collectively highlighting the versatility of chemical compounds that can modulate cyclin C function through the inhibition of CDKs. This class of inhibitors contributes to our understanding of the intricate regulatory networks governing cell cycle progression and the vital role played by cyclin C in these processes.